论文部分内容阅读
目的探讨依那普利联合缬沙坦治疗糖尿病肾病的疗效。方法确诊为糖尿病肾病的64例患者随机分为治疗组32例,在常规糖尿病治疗的同时给予依那普利结合缬沙坦治疗;对照组32例在常规糖尿病治疗的同时单用依那普利治疗。结果两组患者在治疗后UAER较治疗前均有明显改善(P<0.01或P<0.05),而且治疗组明显优于对照组(P<0.05),两组血BUN、SCr治疗前后自身和组间比较差异无统计学意义(P>0.05)。同时两组都无明显不良反应。结论缬沙坦和依那普利联用治疗糖尿病肾病患者较单用依那普利更能显著地降低尿白蛋白,且安全,值得临床推广。
Objective To investigate the efficacy of enalapril combined with valsartan in the treatment of diabetic nephropathy. Methods Sixty-four patients diagnosed with diabetic nephropathy were randomly divided into treatment group (n = 32) and enalapril combined with valsartan (n = 30). The control group (n = 32) was enalapril combined with conventional diabetes mellitus treatment. Results After treatment, UAER in both groups were significantly improved (P <0.01 or P <0.05), and the treatment group was significantly better than the control group (P <0.05) There was no significant difference between the two groups (P> 0.05). At the same time, there was no obvious adverse reaction in both groups. Conclusion Combination valsartan and enalapril treatment of diabetic nephropathy patients with enalapril alone more significantly reduce urinary albumin, and safe, worthy of clinical promotion.